KR20150012711A - Composition comprising lycium chinensis for improving immunity reinforcement - Google Patents
Composition comprising lycium chinensis for improving immunity reinforcement Download PDFInfo
- Publication number
- KR20150012711A KR20150012711A KR1020130088562A KR20130088562A KR20150012711A KR 20150012711 A KR20150012711 A KR 20150012711A KR 1020130088562 A KR1020130088562 A KR 1020130088562A KR 20130088562 A KR20130088562 A KR 20130088562A KR 20150012711 A KR20150012711 A KR 20150012711A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- water
- present
- leukopenia
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 230000036039 immunity Effects 0.000 title claims abstract description 31
- 244000241872 Lycium chinense Species 0.000 title 1
- 230000002787 reinforcement Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000002904 solvent Substances 0.000 claims abstract description 29
- 201000002364 leukopenia Diseases 0.000 claims abstract description 23
- 231100001022 leukopenia Toxicity 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 230000006872 improvement Effects 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001965 increasing effect Effects 0.000 abstract description 13
- 235000013305 food Nutrition 0.000 abstract description 8
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 4
- 239000005445 natural material Substances 0.000 abstract description 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000009610 hypersensitivity Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition for improving immunity, and more particularly, to a composition for improving immunity and a composition for preventing and treating leukopenia.
According to the composition for preventing and treating immunity-enhancing and leukopenia-induced hypersensitivity and the method for preparing the same, which are proposed in the present invention, it is possible to produce a composition using an extract of Ganoderma lucidum, which is a natural substance, as an effective ingredient, Prevention and Improvement Therapeutic effect, can be ingested by adding to drink and various foods.
In addition, according to the present invention, by extracting Gujilus with a specific solvent, temperature and time, it can exhibit the most effective and economical effect of increasing immunity and increasing leukocyte count.
Description
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for enhancing immunity, and more particularly to a composition for enhancing immunity comprising a Gujuga extract.
Immunity is a phenomenon in which the inner environment of a living body defends against an antigen, which is an external factor, and external factors include a pathogenic microorganism or a product thereof, a food, a chemical substance, a medicine, and a pollen. If the immune system is inadequate, the possibility of acquiring cancer, other intractable diseases as well as infectious diseases such as colds, Behcet's disease, and shingles is increased. Therefore, in order to lead a healthy life, efforts to increase immunity are needed. Immunostimulants have been shown to increase cellular and humoral immunity against antigens for the first time by the Romanian concept of the concept (Roman G., Bull. Soc. Centr. Med. Vet., 101, 277, (Rajesh K. Gupta et al., Vaccine, 11: 293, 1993). Examples of the mechanism of action of the immunostimulating agent that raises various immunological actions in vivo in the antigen include activation of antigen-presenting cells (for example, macrophages and the like) and specific activity effects on lymphocytes (Waksman BH, Springer Semin, Immunopathol., 2: 5, 1979; Bomford, R., Clin. Exp. Immunol., 39: 435, 1980).
Such an immunostimulant is developed by an immunomodulating composition comprising interferon-gamma as an active ingredient or a composition containing ginsenoside (see Patent Application Nos. 10-2005-0077233 and 10-2003-0021617) Recently, an immunostimulating pharmaceutical composition using a herbal medicine such as hamcho or ginseng extract has been developed (see Patent Application No. 10-2009-0014476, 10-2007-0099584, etc.).
Leukopenia, on the other hand, is a condition in which blood leukocyte levels are reduced below normal levels, often caused by infection or drugs. Leukocyte is to protect the body by protecting against the infection by eating the foreign body or bacteria in the blood and tissue or forming the antibody, so if the white blood cell count is low, the immunity is weak and it is likely to be exposed to various diseases . In the past, leukopenia was managed by administering food to enhance immunity, or, in severe cases, antibiotics were used depending on the cause.
Drugs using chemical compounds currently in research and development have not been tested for adverse effects in the long term, and therefore, there is a problem in that it is difficult to continuously use them for prevention. On the other hand, compositions for health food using herbal medicines are merely mixed with materials known to have various effects as herbal medicines, or only for proving the immunity enhancing effect against some medicines. Accordingly, the present inventors have developed a composition for prevention and treatment of immune enhancement and leukopenia, which are less likely to be adversely affected, and easy to be handled and consumed, by using natural products, not chemical medicines.
The present invention has been proposed in order to solve the above-mentioned problems of the previously proposed methods, and it has been found that by preparing a composition containing an extract of Ganoderma lucidum, which is a natural substance, as an active ingredient, there is little side effect, and effective immune enhancement and leukopenia prevention / It is an object of the present invention to provide a composition for prevention and treatment of immune enhancement and leukopenia reduction, which contains gugija extract, which can be ingested by adding it to a drink or a variety of foods, and its preparation method.
The present invention also relates to a method for preventing and treating leukopenia and immunosuppression including Gugija extract which can exhibit the most effective and economical effect of increasing immunity and leukocyte count by extracting Gugija at a specific solvent, And to provide a composition and a method for producing the same.
According to an aspect of the present invention, there is provided an immunoconjugate composition comprising:
It is characterized by its constitution that the extract of Gujuga extract is contained as an active ingredient.
Preferably,
The gugija extract is obtained by extracting water, alcohol or a mixture thereof with a solvent, and the composition for enhancing immunity can be used as a health functional food.
Preferably, the Gujuga extract comprises,
Or water-extracted at 98 to 110 ° C for 3 to 7 hours or ultrasonically extracted at 30 to 60 ° C for 1 to 5 hours using water as a solvent.
In order to achieve the above object, the present invention provides a composition for preventing and treating leukopenia,
It is characterized by its constitution that the extract of Gujuga extract is contained as an active ingredient.
Preferably, the composition for preventing and ameliorating leukopenia comprises,
And further comprising a pharmaceutically acceptable carrier,
The Gujiri extract may be contained in an amount of 20 to 60% by weight based on the total weight of the composition for preventing and ameliorating leukopenia.
According to an aspect of the present invention, there is provided a method for preparing an immunoconjugate composition,
(1) adding water, alcohol or a mixture thereof to an extractor as an extraction solvent, and applying heat or ultrasonic waves to obtain an extract;
(2) filtering the extract obtained in the step (1) to recover the filtrate; And
(3) heating the recovered filtrate.
Preferably, the step (1)
And heating the solution at 98 to 110 ° C. for 3 to 7 hours using water as an extraction solvent.
Preferably, the step (1)
And water is extracted as an extraction solvent and subjected to ultrasonic extraction at 30 to 60 ° C for 1 to 5 hours.
According to the composition for preventing and treating immunity-enhancing and leukopenia-induced hypersensitivity and the method for preparing the same, which are proposed in the present invention, it is possible to produce a composition using an extract of Ganoderma lucidum, which is a natural substance, as an effective ingredient, Prevention and Improvement Therapeutic effect, can be ingested by adding to drink and various foods.
In addition, according to the present invention, by extracting Gujilus with a specific solvent, temperature and time, it can exhibit the most effective and economical effect of increasing immunity and increasing leukocyte count.
FIG. 1 is a graph showing the results of detection of polyphenol contents after hot water extraction using water, 50% ethanol, and 100% ethanol as solvents, respectively, in the composition for enhancing immunity according to an embodiment of the present invention.
FIG. 2 is a graph showing the results of HPLC analysis after hot-water extraction using water and 70% ethanol as solvents, respectively, in the composition for enhancing immunity according to an embodiment of the present invention. FIG.
3 is a view showing a flow of a method for manufacturing a composition for immunostaining according to an embodiment of the present invention.
FIG. 4 is a graph showing the results of an experiment for increasing the leukocyte level of the composition for improving immunity according to an embodiment of the present invention. FIG.
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. In the following detailed description of the preferred embodiments of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear. The same or similar reference numerals are used throughout the drawings for portions having similar functions and functions.
In addition, in the entire specification, when a part is referred to as being 'connected' to another part, it may be referred to as 'indirectly connected' not only with 'directly connected' . Also, to "include" an element means that it may include other elements, rather than excluding other elements, unless specifically stated otherwise.
In the present specification, the term " active ingredient " includes a substance or a group of substances expected to directly or indirectly express the efficacy of the composition by an inherent pharmacological action (pharmacologically active ingredients, etc., Quot; means that the main component is included.
TECHNICAL FIELD The present invention relates to a composition for improving immunity, which comprises an extract of Gugeyanggi as an active ingredient. Preferably, the gugija extract may contain betaine in an amount of 0.3 to 0.7 mg / g based on the total weight of the gugija extract.
In addition, according to the embodiment, the extract may further contain, as an active ingredient, jujube, omija, yongji, angiji, licorice, etc. In this case, the gugija extract may be contained in an amount of 50 to 80% by weight based on the total weight of the composition for enhancing immunity have. In the present invention, by using the jujube, omija, ganoderma, Angelica gigas, and licorice, among various medicines, the flavor can be improved, and the immunity enhancing effect and the leukocyte count increasing effect can be further increased.
In addition, in the composition for improving immunity proposed in the present invention, the extract of Gujuga may be obtained by extracting water, alcohol or a mixture thereof with a solvent. FIG. 1 is a graph showing the results of detection of polyphenol contents after hot water extraction using water, 50% ethanol and 100% ethanol as solvents as a composition for immunomodulation according to an embodiment of the present invention. The composition for enhancing immunity comprising the extract of Gugeyaggi according to one embodiment of the present invention is subjected to hot extraction using water, 50% ethanol and 100% ethanol as a solvent, and then the total polyphenol content of the hot water extract is measured as tannic acid . As a result of the measurement, as shown in Fig. 1, 19.0 mg / g of the hot-water extract (a) as a solvent of water, 7.7 mg / g of the hot-water extract (b) of 50% ethanol as a solvent, 100% (C) contained a total polyphenol content of 6.9 mg / g. As a result, it was confirmed that hot extraction of water with a solvent is an effective solvent that has the highest concentration of goji.
FIG. 2 is a graph showing the results of HPLC analysis after hot-water extraction using water and 70% ethanol as a solvent in the immunoconjugate composition according to an embodiment of the present invention. FIG. As shown in FIG. 2, the HPLC pattern trends of the polyphenols of the hot water extraction (water extract) and the hot water extract (70% ethanol extract) using 70% ethanol as a solvent were similar, Water extracts were higher than the others. This is because, as shown in the results of the total polyphenol content test described with reference to FIG. 1, the hot water extract using water as a solvent is highly extracted in the overall polyphenol content. Therefore, in the present invention, desirable. Preferably, the extract of the present invention may be obtained by extracting hot water at 98 to 110 ° C for 3 to 7 hours or ultrasonically extracted at 30 to 60 ° C for 1 to 5 hours using water as a solvent.
The composition for enhancing immunity proposed in the present invention may be added to food, or may be used as a health functional food which can be prepared as a drink, pill or the like and mixed with other foods. It may also be used as a pharmaceutical composition such as an immunostimulating agent.
According to another aspect of the present invention, there is provided a composition for prevention and treatment of leukopenia including an extract of Ganoderma lucidum as an active ingredient. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier. The extract may contain 20 to 60% by weight, based on the total weight of the composition for preventing and ameliorating leukopenia. Pharmaceutically acceptable carriers may include, but are not limited to, physiological saline, polyethylene glycol, ethanol, vegetable oils, and isopropyl myristate.
The pharmaceutical dosage form of the composition for preventing and ameliorating leukopenia according to an embodiment of the present invention may be used in the form of pharmaceutically acceptable salts thereof, and may be used alone or in combination with other pharmaceutically active compounds, It can also be used as a set.
The composition for preventing and treating leukopenia according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral formulations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions Can be used. Examples of carriers, excipients and diluents that can be included in the composition proposed in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, There may be mentioned calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. A diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like are prepared . Examples of the preparation for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations and suppositories. Non-aqueous solvents and suspensions include vegetable oils such as propylene glycol, polyethylene glycol and olive oil , Injectable esters such as ethyl oleate, and the like can be used.
The composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. The method of administration is not limited and can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intramural or intracerbroventricular injection. The preferred dosage depends on the condition and the weight of the patient, the degree of the disease, the form of the drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. Preferably, however, it can be administered at a daily dose of 0.001 to 100 mg / kg of body weight per day, more preferably 0.01 to 30 mg / kg of body weight per day. The administration can be carried out once a day or divided into several doses.
Yet another aspect of the present invention provides a method for preparing a composition for immunostaining. 3 is a view showing a flow of a method for manufacturing a composition for immunostaining according to an embodiment of the present invention. As shown in FIG. 3, the method for preparing an immunomodulating composition according to an embodiment of the present invention comprises the steps of adding water, a liquor or a mixture thereof to an extractor as an extraction solvent, and adding an extract or heat S100), filtering the extracted liquid obtained in step S100 to recover the filtrate (S200), and heating the recovered filtrate (S300).
In step S100, water can be added to the ginger as an extraction solvent and heated to obtain a hot-water extract solution, which may be heated at 98 to 110 ° C for 3 to 7 hours, depending on the embodiment. Most preferably, it can be heated at 100 DEG C for 6 hours. Further, according to another embodiment, ultrasonic extraction may be performed at 30 to 60 ° C for 1 to 5 hours using water as an extraction solvent. In step S300, the filtrate filtered in step S200 may be heated to remove oil components and other impurities which may interfere with the action and effect of the pig-tail.
The present invention is explained in more detail by the following examples, but the present invention is not limited in any way by the following examples.
The In one embodiment For the preparation of a composition for preventing and treating leukopenia and for improving immunity
And 350 g of water and 1 L of water were placed in a flask and heated at 100 DEG C for 6 hours to obtain a hot water extract solution. The obtained hot water extract was filtered to recover the filtrate, and the recovered filtrate was concentrated under reduced pressure.
Hereinafter, the effects of the present invention will be described in more detail through experimental examples, but the scope of the present invention is not limited by the following experimental examples.
Experimental Example 1. Measurement of cytokine secretion
Animal experiments were carried out as follows to confirm the immunopotentiation effect of the composition for enhancing immunity comprising the extract of Aspergillus oryzae according to Example 1 as an active ingredient.
1. Subject, Period and Experiment Method
Experimental subjects were given 6 weeks old mice (18-20g) of a specific pathogen member (SPF) of the C57BL / 6 lineage and assigned 6 mice per experimental group. Experimental groups were divided into four experimental groups (1 mg (intake) / kg (body weight), 10 mg / kg, 100 mg / kg) and scavenging groups according to the concentration of the composition prepared according to Example 1. Diets were fed free of solid feed for laboratory animals and water was freely consumed. When animals were obtained, their appearance was visually inspected, followed by testing for one week. In general, only the healthy animals were used for the test. The weight of the mouse at 7 weeks old at the start of administration of the composition was 20 to 22 g in the composition intake group prepared according to Example 1. This test is carried out in a laboratory animal room set at a temperature of 23 ± 3 ° C, a relative humidity of 50 ± 10%, a lighting time of 12 hours (lit at 09 o'clock and lights out at 21 o'clock), 10-20 times per hour of ventilation and an illuminance of 150-300 Lux Respectively. The gugija extract was dissolved in sterilized water in an amount of 1 g per day for a person who weighed 60 kg, and the mice in the ingestion group were freely ingested for 3 weeks at the respective concentrations. After the end of the 3-week intake, the mice were excised from the cervical vertebra and the thymus and spleen were excised to determine the concentration of interleukin-2 (IL-2) and interferon-γ (IFN-γ) Were measured by ELISA. Namely, a goat anti-mouse cytokine antibody was reacted with a coating buffer in a plate microwell plate overnight at 4 ° C and blocked with 3% bovine serum albumin (BSA) solution at room temperature for 2 hours. The culture supernatant collected in the previous experiment was placed on each of the above plates, reacted at 37 ° C for 2 hours, and 0.1 μg / ml of a biotin anti-cytokine secondary antibody was added. Subsequently, an appropriate amount of avidin-conjugated alkaline phosphate was added, reacted at 37 ° C for 2 hours, p-nitrophenyl phosphate was added as a substrate, and absorbance values were measured at 410 nm and 450 nm using a microplate reader.
2. Results
Table 1 shows the results of measurement of IL-2 and IFN-y secretion levels in the mouse spleen of the composition prepared according to Example 1 and in the group of mice fed with the concentration of Gugija extract, by the concentration of Gugija extract.
(Mg / kg)
As shown in Table 1, the amount of IL-2 and IFN-y secretion was significantly increased in the ingestion group as compared with that of the uninfected group by the extract of Gujuga extract.
Experimental Example 2. Leukocyte count change experiment
The human body experiment was carried out as follows to confirm leukocyte level increasing effect by the composition for prevention and remedy of leukopenia reduction, which comprises as an active ingredient the gugija extract prepared according to Example 1.
1. Subject, duration and method
In order to investigate the effect of gugija on the immunity enhancement, gugija extract (1 g / day) was administered to 20 recipients of 40 experimental groups and the number of white blood cells in 1 ㎕ of blood was observed after 7 days.
2. Results
Table 2 and FIG. 4 show the mean values of leukocyte change amounts of the composition ingestion group and the scavenging group prepared according to Example 1.
As shown in Table 2 and Fig. 4, it can be seen that the number of leukocytes in the ingested group was increased as compared with that of the control group. Through this experiment, it was confirmed that the composition proposed in the present invention has an effect of preventing and treating leukopenia. In addition, White Blood Cell maintains the body's immune system through the action of protecting the body from infection and resistance by ingesting foreign substances or germs in the blood and tissues or forming antibodies, . Therefore, it can be seen that the immunity is enhanced through the ingestion of Gojiji.
Thus, Gugija extract has the effect of increasing white blood cell count and enhancing body immunity function, which can contribute to health maintenance and enhancement for all aged people who have impaired immune function. Also, it is expected that Gugija extract can be safely applied to a health supplement food composition because it has no cytotoxicity and skin side effect using natural substance as an active ingredient.
The present invention may be embodied in many other specific forms without departing from the spirit or essential characteristics of the invention.
S100: adding water, alcohol or a mixture thereof to an extractor as an extraction solvent, and applying heat or ultrasonic waves to obtain an extract
S200: the step of filtering the extract obtained in the step S100 and recovering the filtrate
S300: Reheating the recovered filtrate
Claims (8)
The composition for immunity enhancement according to claim 1, wherein the gugija extract is obtained by extracting water, alcohol or a mixture thereof with a solvent, and the immunoconjugation composition is used as a health functional food.
Wherein the composition is subjected to hot water extraction at 98 to 110 ° C for 3 to 7 hours or ultrasonic extraction at 30 to 60 ° C for 1 to 5 hours using water as a solvent.
And further comprising a pharmaceutically acceptable carrier,
The composition for preventing and treating leukopenia is characterized by comprising 20 to 60% by weight based on the total weight of the leukopenia preventive and remedy composition.
(2) filtering the extract obtained in the step (1) to recover the filtrate; And
And (3) heating the recovered filtrate.
And heating the mixture at 98 to 110 DEG C for 3 to 7 hours using water as an extraction solvent.
And water is extracted with an ultrasonic wave at 30 to 60 ° C for 1 to 5 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130088562A KR20150012711A (en) | 2013-07-26 | 2013-07-26 | Composition comprising lycium chinensis for improving immunity reinforcement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130088562A KR20150012711A (en) | 2013-07-26 | 2013-07-26 | Composition comprising lycium chinensis for improving immunity reinforcement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150012711A true KR20150012711A (en) | 2015-02-04 |
Family
ID=52488688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130088562A KR20150012711A (en) | 2013-07-26 | 2013-07-26 | Composition comprising lycium chinensis for improving immunity reinforcement |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150012711A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200086914A (en) * | 2019-01-10 | 2020-07-20 | 주식회사농심 | Composition for enhancing immunity, pharmaceutical and functional food having the composition |
| US11779626B2 (en) | 2018-01-05 | 2023-10-10 | Cosmax Ns, Inc. | Composition for enhancing immunity or preventing or treating neurodegenerative diseases by using goji berries, mulberries and jujubes |
-
2013
- 2013-07-26 KR KR1020130088562A patent/KR20150012711A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11779626B2 (en) | 2018-01-05 | 2023-10-10 | Cosmax Ns, Inc. | Composition for enhancing immunity or preventing or treating neurodegenerative diseases by using goji berries, mulberries and jujubes |
| KR20200086914A (en) * | 2019-01-10 | 2020-07-20 | 주식회사농심 | Composition for enhancing immunity, pharmaceutical and functional food having the composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6305407B2 (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| KR100511550B1 (en) | Pharmaceutical composition comprising the extract of Actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | |
| CA2483620C (en) | Compositions for preventing or treating pollenosis, allergic nephritis, atopic dermatitis, asthma or urticaria | |
| KR101011028B1 (en) | Composition for Promoting Proliferation of Hematopoietic Stem Cell Containing Inonotus obliquus extract, Phellinus linteus extract and Ganoderma lucidum extract | |
| AU2009219793B2 (en) | Activation of innate and adaptive immune responses by a ginseng extract | |
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| EP3443972A1 (en) | Pharmaceutical composition for preventing or treating respiratory disease comprising extract of justicia procumbens l. | |
| KR20130019352A (en) | A composition comprising the extract of cudrania tricuspidata trunk as an active ingredient for preventing and treating atopic diseases | |
| KR101130139B1 (en) | Composition for preventing calves diarrhea | |
| KR20150012711A (en) | Composition comprising lycium chinensis for improving immunity reinforcement | |
| KR20060092373A (en) | Herb medicinal compositions for prevention and alleviation of childern's atopic eczema or dermatitis | |
| CN102166183B (en) | Immunologic stimulant oral syrup and preparation method thereof | |
| KR20090071704A (en) | Composition for prevention and treatment of the dementia | |
| KR20130130407A (en) | Composition for enhancing immunity comprising extract of hazel pollen as effective component | |
| EP1709995A1 (en) | Asthma/allergy therapy using nigella sativa | |
| US20110224160A1 (en) | Use of Escin for Treatment of Type IV Hypersensitivity Reaction | |
| US20130071435A1 (en) | Novel herbal formulation for the modulation of immune system of hiv infected patients and a process of preparation thereof | |
| KR100207293B1 (en) | Immunostimulating composition containing mixed aqueous extract of phellodendri cortex and patrinia scabiosaefolia | |
| KR101054020B1 (en) | Composition for preventing and treating allergic diseases containing Camellia seed oil extract of longevity situation mushroom | |
| KR100750873B1 (en) | A pharmaceutical composition comprising the extract of Rubiae Radix for treating or preventing allergic disease | |
| KR101671571B1 (en) | A ginseng seed composition having inhibitory effect of glucose absorption and preparing method thereof | |
| KR102356654B1 (en) | An anti-inflammatory and analgesic formula comprising propolis and goji berry | |
| WO2023204364A1 (en) | Composition for prevention, amelioration or treatment of allergic respiratory diseases comprising alpinia officinarum hance extract as active ingredient | |
| CN109568564B (en) | Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application | |
| JP2007091735A (en) | Method for preventing or treating allergy, food and drink, and oral medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |